Glycemic Control
Glycemic control encompasses fasting plasma glucose, HbA1c, and post-prandial glucose excursion management. The incretin axis is the dominant pharmacological target; GLP-1 and GIP receptor agonism drives glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying. Tirzepatide and retatrutide are the current state-of-the-art compounds.
